A Study to Evaluate the Safety, Tolerability, PK and PD of AP303 in DKD Patients

NCT06666283 · clinicaltrials.gov ↗

PHASE1

Phase

RECRUITING

Status

18

Enrollment

INDUSTRY

Sponsor class

Conditions

Diabetic Kidney Disease

Interventions

DRUG: AP303 150μg
DRUG: Placebo 150μg

Sponsor

Alebund Pharmaceuticals